Salinomycin
Salinomycin has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 18, 2024: “An antibiotic that mediates immune destruction of senescent cancer cells”.
- 1 lab in 2 countries
- Funders: Basic and Applied Basic Research Foundation of Guangdong Province and 7 more
- Animals1
What did studies of Salinomycin find?
2Studies of Salinomycin measured 2 outcomes; the most studied are TNFRSF10B (1 study) and PANoptosis (1).
TNFRSF10B
upin human cells1
1 study
TNFRSF10B
upin human cells1
Salinomycin increases TNFRSF10B in human cells.
“salinomycin treatment or SLC25A23 suppression elevates reactive oxygen species, upregulating death receptor 5 via Jun N-terminal protein kinase (JNK) pathway activation.”
Cellssenescent cancer cells
An antibiotic that mediates immune destruction of senescent cancer cells
Proceedings of the National Academy of Sciences of the United States of America
PANoptosis
upin human cells1
1 study
PANoptosis
upin human cells1
Salinomycin induces PANoptosis in human cells.
“Salinomycin prompts a pyroptosis-apoptosis-necroptosis (PAN)optosis-like cell death in senescent cells”
Cellssenescent cancer cells
An antibiotic that mediates immune destruction of senescent cancer cells
Proceedings of the National Academy of Sciences of the United States of America